Overview of IBA's Share Buyback Program
IBA, a leading company in particle accelerator technology, recently implemented a share buyback program aimed at enhancing shareholder value. This initiative, announced earlier, allows IBA to repurchase a maximum of 650,000 ordinary shares under a mandate that remains in effect until the last day of the year. It underscores IBA's commitment to its long-term incentive plans that benefit both its management team and select personnel.
Recent Share Transactions
As part of this active buyback program, IBA has successfully repurchased a total of 71,276 shares from the market over a short period. Significant transactions occurred on key dates with distinct price points that highlight IBA's strategic approach to the buyback. For instance, on April 30, 2025, a notable block of 50,000 shares was purchased at a price of €10.22 each.
Details of Transactions
Here's a summarized look at IBA's recent transactions that were part of the buyback initiative:
- **April 29, 2025:** 8,000 shares bought at an average price of €10.31.
- **April 30, 2025:** 6,000 shares at €10.33, including the notable 50,000 block at €10.22.
- **May 4, 2025:** 6,000 shares at €10.59.
- **Final Day of This Report:** 1,276 shares purchased at €10.99.
These transactions not only reflect IBA’s investment in its own value but also show confidence in its future performance.
Impact on Treasury Shares
Following these recent buyback activities, the total number of treasury shares held by IBA has reached an impressive 910,845 shares. This figure holds significance as it impacts the overall voting rights within the company, influencing decision-making and shareholder dynamics.
Breakdown of Treasury Shares and Voting Rights
The current holder distribution for treasury shares reveals ongoing support for IBA's governance:
- IBA Investments SRL: 51,973 shares representing 103,946 voting rights.
- IBA SA: 858,872 shares correlating to 925,295 voting rights.
This robust treasury management illustrates IBA's proactive approach to ownership and controls.
About IBA
Founded in Louvain-la-Neuve, Belgium, IBA leads the industry with cutting-edge particle accelerator technology. The company specializes in proton therapy, which is recognized as the most advanced method in radiation therapy available today, among other services such as industrial sterilization and dosimetry. With a global workforce of around 2,100, IBA stands out not only in technology but also as a certified B Corporation, reflecting its commitment to social and environmental responsibility.
Listing Information
As a testament to its growth, IBA is listed on the pan-European stock exchange EURONEXT, trading under the ticker symbol IBAB. This public presence enhances transparency and provides investors with direct insights into the company’s operations.
Frequently Asked Questions
What is the purpose of IBA's share buyback program?
The program aims to enhance shareholder value and cover obligations under long-term incentive plans.
How many shares has IBA repurchased through this program?
As of now, IBA has repurchased a total of 71,276 shares.
What are the implications of the treasury shares for IBA?
Treasury shares affect voting rights and influence governance decisions within the company.
Where is IBA based?
IBA is located in Louvain-la-Neuve, Belgium.
What industries does IBA serve?
IBA serves the healthcare field primarily through proton therapy and also provides solutions for industrial sterilization and dosimetry.
